Skip to main content

This job has expired

You will need to login before you can apply for a job.

Senior Scientist I/II (HTP Screening)

Employer
Mammoth Biosciences
Location
Brisbane, CA
Start date
Jun 7, 2024

View more

Discipline
Science/R&D, Biotechnology
Required Education
Bachelors Degree
Position Type
Full time
Hotbed
Biotech Bay

Job Details

OPPORTUNITY
Mammoth Biosciences is seeking a Senior Scientist I/II within its Screening & Process Automation team to drive the development of cell-based screening workflows. The Screening & Process Automation team implements and maintains pooled and arrayed screening processes to accelerate progress across technology development and drug discovery projects. The successful candidate will focus on the development of semi-automated arrayed screening processes with human and mouse derived cell lines. Cross-team collaboration will be a central component of this role as the Senior Scientist will work closely with project scientists to define process specifications and validate process performance. This position will include opportunities for professional development and career advancement.

KEY RESPONSIBILITIES
  • Workflow Scale-up: Take ownership of the scale up of a bench-scale workflow to high-throughput automated workflow 
  • Statistical Analysis: Conduct rigorous statistical analysis of all parameters of the process needed to define success including DOE and power analysis
  • Experimentation: Execution of experiments to improve screening workflows through rigorous testing multiple parameters to identify conditions that maximize performance
  • Reagent Production: Design and produce DNA and mRNA and cell-based reagents to perform arrayed transfections with diverse mammalian cell lines
  • Training: Train colleagues to perform HTP screening workflows that have been developed  
  • Maintenance and Troubleshooting: Regular maintenance of performance of HTP screening workflows and troubleshooting when necessary
  • Collaboration: Work closely across teams to reach the desired goal through problem-solving, teamwork, clear communication, and adaptability

REQUIRED QUALIFICATIONS
  • PhD in Molecular Biology, Cell Biology, Biochemistry, Biomolecular Engineering or a related discipline 
  • Minimum of 3 years relevant professional experience in industry following completion of PhD or 8 years of professional experience for non-PhD candidates with a Bachelor's degree 
  • Hands-on experience in automated methods for high throughput evaluation of DNA- or mRNA-encoded proteins in human or mouse cell lines
  • Demonstrated proficiency in applying statistical methods to experimental design and data analysis

PREFERRED QUALIFICATIONS
  • 5 years of biotechnology industry experience
  • 2 years of experience developing tools or workflows for (epi)genome editing applications
  • Computer and scripting skills (Benchling, Geneious, JMP, SQL, R, Python, Prism)
  • Experience with HTP mRNA production and screening in mammalian cell lines
  • Experience with viral vector payload design, production and in vitro screening in mammalian cells

BENEFITS
  • Company-paid health/vision/dental benefits
  • Unlimited vacation and generous sick time
  • Company-sponsored meals and snacks
  • Wellness, caregiver and ergonomics benefits
  • 401(k) with company matching

Base Salary Range: $ 155,000 - $182,350

The listed base salary range is for Mammoth employees in the Bay Area. Actual base salary will be determined by geographic work location, relevant professional experience, applicable skills, and internal equity. The base salary range for those working remotely outside of the San Francisco Bay Area may differ and will be determined by industry market data for the role and specific region.

Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop long-term curative therapies, as well as other applications such as decentralized precision diagnostics. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, the company’s ultracompact proteins are designed to enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities beyond double stranded breaks, including base editing, gene writing, and epigenetic editing. The company is building out its pipeline of potential in vivo gene editing therapeutics and capabilities and has partnerships with leading pharmaceutical and biotechnology companies to broaden the reach of its innovative and proprietary technology. Mammoth’s deep science and industry experience, along with a robust and differentiated intellectual property portfolio, have enabled the company to further its mission to transform the lives of patients and deliver on the full promise of CRISPR technologies.

It is our policy and intent to provide equal opportunity to all persons without regard to race, color, religion, political affiliation, sex/gender (including gender expression/identity, pregnancy, childbirth and related medical conditions), marital status, registered domestic partner status, sexual orientation, age, ancestry, national origin, veteran status, disability, medical condition, genetic characteristics, and/or any other basis protected by law. This policy covers all facets of employment including, but not limited to: recruitment, selection, placement, promotions, transfers, demotions, terminations, training, and compensation.

Mammoth Biosciences requires that all employees be vaccinated against COVID-19 as a condition of at-will employment, with exceptions for medical or religious reasons in compliance with local, state, and federal law. 

Company

Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop long-term curative therapies, as well as other applications such as decentralized precision diagnostics. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, the company’s ultracompact proteins are designed to enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities beyond double stranded breaks, including base editing, gene writing, and epigenetic editing. The company is building out its pipeline of potential in vivo gene editing therapeutics and capabilities and has partnerships with leading pharmaceutical and biotechnology companies to broaden the reach of its innovative and proprietary technology. Mammoth’s deep science and industry experience, along with a robust and differentiated intellectual property portfolio, have enabled the company to further its mission to transform the lives of patients and deliver on the full promise of CRISPR technologies.

Facebook  Twitter  Instagram

Company info
Website
Phone
(650) 294-8583
Location
South San Francisco
CA
94080
US

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert